Postdoctoral positions
Postdoctoral Position in Metastasis Research
A position for a POSTDOCTORAL RESEARCHER is open in the group of “Cancer Stem Cell Biology” at the Swiss Institute for Cancer Research (ISREC) within the École Polytechnique Fédérale de Lausanne (EPFL).
Our research is focused on tumor-stroma interactions in various solid tumors (breast, colon and pancreatic cancer) using genetically engineered mouse models and patient samples (Nature 2008, 452:650-3; Nature. 2011, 481:85; Cancer Cell 2015, 28:815). In particular, we are interested to understand how alterations of the tumor-associated stroma at the primary site promote the metastatic abilities of tumor cells. Further, we aim to elucidate mechanisms of metastatic colonization, i.e. how tumors modulate immune and other stromal factors to facilitate outgrowth at a secondary site. This project is supported by grants from the SNF and the Pictet group.
The group offers a creative international environment with the possibility to carry out high level research in an exciting and rapidly moving field. We are looking for an outstanding candidate with a track record of high quality publications and experience in tumor immunology, animal experimentation and molecular biology. Self-motivation and ability to work independently as well in a group are essential. Good knowledge of English (oral and written) is mandatory. Salary is available for three years; grant submissions are encouraged.
Your application shall contain a CV, motivation letter and 3 reference letters and/or the names of 3 referees. For more information, please contact Prof. Dr. Joerg Huelsken (email).
PhD positions
PhD positions are available on a regular basis. We aim to better define immune evasion and suppression mechnisms, tumor-stroma interactions in metastasis and differentiation processes in tumor cells which affect phenotypic heterogeneity and stemness. Our engineering activities concentrate on the development of microfluidic platforms for functional analysis of single cells and on the design of novel chimeric antigen receptor (CAR) T cell immunotherapies. For more information, please contact Prof. Dr. Joerg Huelsken (email).